Ind-Swift Laboratories Ltd.

Financial

	Ind-Swift Lab.	Albert David	Jenburkt Pharma
Operational Metrics
API Sector
Total reactor capacity	700.0 kL	n/a	n/a
DMF Filingsby API	474.0 .	n/a	n/a
Pharmaceutical Sector
R&D as a % of Total Sales	3.01 %	0.54 %	0.87 %
Financials
5 yr Average ROE	9.6 %	12.32 %	18.48 %
5yr average Equity Multiplier	2.49	1.67	1.2
5yr Average Asset Turnover Ratio	0.67	0.67	0.95
5yr Avg Net Profit Margin	6.7 %	11.52 %	16.38 %
Price to Book	0.51	1.21	3.05
P/E	2.14	12.32	15.3
5yr Avg Cash Conversion Cycle	76.78 Days	-59.38 Days	-16.2 Days
Inventory Days	126.74 Days	46.72 Days	26.89 Days
Days Receivable	95.44 Days	28.39 Days	46.84 Days
Days Payable	94.9 Days	118.01 Days	76.62 Days
5yr Average Interest Coverage Ratio	3.49	90.39	75.84
5yr Avg ROCE	12.63 %	15.83 %	24.52 %
5yr Avg Operating Profit Margin	19.31 %	11.27 %	20.46 %
5 yr average Debt to Equity	1.22	0.01	0.03
5yr CAGR Net Profit	n/a	31.51 %	11.81 %
5yr Average Return on Assets	7.66 %	7.45 %	15.36 %
Shareholdings
Promoter Holding	40.94 %	62.24 %	46.68 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-1.06 %	0.28 %	0.95 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

Business

	Ind-Swift Lab.	Albert David	Jenburkt Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Dermatology 0	Product Wise Break-Up Pharmaceutical 0 Dermatology 0 Others 100	Product Wise Break-Up Pharmaceutical 0 Dermatology 0 Others 100
Location Wise Break-Up	Location Wise Break-Up India 21.75 Rest of the World 0 Others 78.25	Location Wise Break-Up India 92.79 Rest of the World 7.21	Location Wise Break-Up India 85.66 Rest of the World 14.1 Others 0.24
Operating Profit Break-Up	Operating Profit Break-Up India 18.87 Others 81.13	-	-
Asset Break-Up	Asset Break-Up India 67.55 Others 32.45	-	-